Reduction of apoptosis and preservation of mitochondrial integrity under ischemia/reperfusion injury is mediated by estrogen receptor β by Schubert, C. et al.
RESEARCH Open Access
Reduction of apoptosis and preservation of
mitochondrial integrity under ischemia/
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Abstract
Background: Estrogen improves cardiac recovery after ischemia/reperfusion (I/R) by yet incompletely understood
mechanisms. Mitochondria play a crucial role in I/R injury through cytochrome c-dependent apoptosis activation.
We tested the hypothesis that 17β-estradiol (E2) as well as a specific ERβ agonist improve cardiac recovery through
estrogen receptor (ER)β-mediated mechanisms by reducing mitochondria-induced apoptosis and preserving
mitochondrial integrity.
Methods: We randomized ovariectomized C57BL/6N mice 24h before I/R to pre-treatment with E2 or a specific ERβ
agonist (ERβA). Isolated hearts were perfused for 20min prior to 30min global ischemia followed by 40min reperfusion.
Results: Compared with controls, ERβA and E2 treated groups showed a significant improvement in cardiac recovery, i.
e. an increase in left ventricular developed pressure, dP/dtmax and dP/dtmin. ERβA and E2 pre-treatment led to a
significant reduction in apoptosis with decreased cytochrome c release from the mitochondria and increased
mitochondrial levels of anti-apoptotic Bcl2 and ACAA2. Protein levels of mitochondrial translocase inner membrane
(TIM23) and mitochondrial complex I of respiratory chain were increased by ERβA and E2 pre-treatment. Furthermore,
we found a significant increase of myosin light chain 2 (MLC2) phosphorylation together with ERK1/2 activation in E2,
but not in ERβA treated groups.
Conclusions: Activation of ERβ is essential for the improvement of cardiac recovery after I/R through the inhibition of
apoptosis and preservation of mitochondrial integrity and can be a achieved by a specific ERβ agonist. Furthermore, E2
modulates MLC2 activation after I/R independent of ERβ.
Keywords: Apoptosis, Estrogen receptor β, Ischemia/reperfusion, Mitochondria, Myosin light chain
Background
Premenopausal women have a decreased risk of ischemic
heart disease compared with age-matched men, suggest-
ing a putative cardioprotective effect related to estrogens
during reproductive age. However, in randomized con-
trol trials, chronic estrogen therapy in postmenopausal
women has not demonstrated readily any cardiovascular
benefit [1, 2]. To clarify these conflicting clinical data,
more mechanistic studies in animal models are needed.
There is ample evidence that 17β-estradiol (E2) protects
from ischemia/reperfusion (I/R) injury in mice [3–7].
Effects of E2 are mainly mediated by estrogen receptors
(ER) α or β in the heart. Which ER protects the female
myocardium under I/R conditions is not fully under-
stood. The role of ERβ is of particular interest, since it
has no significant effects in the reproductive system and
ERβ agonists are being developed for clinical use in dif-
ferent indications [8].
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To study the effects of I/R in rodents, generally either
myocardial infarction (MI) with subsequent reperfusion
or isolated perfused heart systems with global or re-
gional ischemia, i.e., the Langendorff model, have been
used [9]. In the Langendorff model, there is convincing
evidence that hearts of ovariectomized (ovx) mice ex-
hibit a significantly greater degree of I/R injury than
hearts from intact female mice, suggesting that E2 pro-
tects from I/R injury [5, 7, 10]. The administration of E2
reduced infarct size [5, 11, 12] or enhanced functional
recovery in the Langendorff model under I/R conditions
[5, 13, 14]. Some studies suggested a predominant role of
ERβ mediating cardioprotection in females [4, 5, 7, 15],
yet the mechanism is not fully understood. Compared
with WT or ERαKO, ERβKO female hearts exhibited less
functional recovery after I/R [4]. In accordance with these
findings, ovx mice treated for 2 weeks with E2 or the ERβ-
specific agonist DPN prior to I/R exhibited significant bet-
ter functional recovery compared to vehicle-treated ovx
females [7]. Gene expression profiling demonstrated that
E2 effects were mediated by ERβ activation resulting in
upregulation of a number of protective genes involved in
apoptosis/cell death regulation or in stress-activated ki-
nases [7]. Considering the crucial role of mitochondria in
cell survival [16], we hypothesized that the E2-induced
improvement of cardiac recovery might be attributed to re-
duction of apoptosis-mediated myocardial damage through
preservation of mitochondrial integrity by ERβ activa-
tion [17] and tested this hypothesis using a specific ERβ
agonist in parallel with E2 in a Langendorff model in
female ovx mice.
I/R injury has also been shown to lead to myofibrillar
remodeling and to depress Ca2+ sensitivity of myofila-
ments. Myosin light chain 2 (MLC2) plays an important
role in the regulation of muscle contractile activity via
its phosphorylation [18, 19]. Monasky et al. reported that
phosphorylation of MLC2 was significantly reduced in
female WT hearts after I/R compared to baseline [20].
We found recently that E2 controls MLC2 function and
thereby contractility in mice [21]. Therefore, the modu-
lation of MLC2 activation in cardiac tissue by E2 after I/
R and the role of ERβ deserve attention for the identifi-
cation of protective mechanisms and were included in
the present study.
Methods
Animals
Experiments were performed in accordance with the
guidelines of Charité-Universitaetsmedizin, were ap-
proved by the Landesamt für Gesundheit und Soziales
(LaGeSo, Berlin, Germany; G0216/12), and conform to
the Guide for the Care and Use of Laboratory Animals
published by the US National Institutes of health (NIH
Publication No. 85-23, revised 1996). Female C57BL/6N
mice (Janvier) were bilaterally ovariectomized (ovx) at
the age of 10 weeks and kept on soy-free diet (Ssniff,
Soest) for 4 weeks. Before I/R experiments, animals were
randomized into three groups [vehicle treated (un-
treated) or treated either with E2 (0.2 mg/kg body
weight (BW)) [21] or the specific ERβ agonist compound
A (ERβA) (1.6 mg/kg BW; Karobio, Sweden) [22] in vivo
by single i.p. injection 24 h before I/R].
Langendorff heart preparation
Animals were anesthetized with ketamine hydrochloride
(80 mg/ml)/xylazine hydrochloride (12 mg/ml) solution
administered by intraperitoneal injection at a dose of
1 mg/kg BW and anticoagulated with heparin. The
hearts were quickly excised and placed in ice-cold
Krebs–Henseleit buffer containing in millimoles per
liter: 2.1 MgSO4, 118.0 NaCl, 4.7 KCl, 0.06 EDTA, 24.7
NaHCO3, 0.23 KH2PO4, 3.215 CaCl2, and 10.0 glucose.
The aorta was quickly cannulated for retrograde perfusion
at a constant pressure of 80 mmHg using a Langendorff
perfusion apparatus. The apparatus was water-jacketed to
maintain a temperature of the heart at 37 °C. The buffer
was oxygenated with 95 % oxygen/5 % CO2 to maintain a
pH of 7.4. A water-filled latex balloon that was connected
to a pressure transducer was inserted into the left ventricle
(LV). LV diastolic pressure (LVPdia) was set to 12 mmHg.
Heart rate (HR), LV systolic (LVPsys) and LV developed
pressure (LVPdp), as well as dP/dtmin and dP/dtmax,
markers for relaxation and contractility, were measured
and recorded continuously using ISOHEART® Isolated
Heart Data Acquisition Software (Harvard Apparatus,
Massachusetts, USA). The hearts were perfused for a
20-min stabilization period. Following 30 min of global is-
chemia, the hearts were reperfused for a total of 40 min.
Recovery of cardiac function was measured at the end of
40 min of reperfusion and expressed as a percentage of
the rate prior to ischemia. During the Langendorff experi-
ment, the physiological data were monitored continuously
and calculated at the end of I/R in percent of the value at
the start of ischemia.
Determination of necrosis
For determination of necrosis, lactate dehydrogenase
(LDH) was used as biomarker. Effluents of each group
were collected for LDH assay over 3 min directly before
global ischemia and four times over 3 min immediately
after the start of reperfusion. LDH was assayed with the
use of a commercially available assay (L-lactate dehydro-
genase, Roche Applied Science, Mannheim, Germany)
according to the manufacturer’s instructions. Optical
density was measured in duplicate for each sample and
multiplied by the respective coronary flow.
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Apoptosis detection
Frozen tissue from the left ventricles were cut into slides
of 5 μm. Terminal deoxynucleotidyl transferase dUTP
nick end labeling (TUNEL Boehringer, Mannheim,
Germany) method was used to evaluate apoptosis in is-
chemic reperfused heart tissue. Staining was analyzed by
Fluorescent Microscopy (Leica, 40-fold resolution). Re-
sults are expressed according to manufacturer indication
in apoptotic nuclei percentage. Representative pictures
are shown in Fig. 3.
Western blot and fractioning of the heart
Whole cell extracts were isolated using modified RIPA
buffer and separated by SDS-polyacrylamide gel electro-
phoresis as previously described [22]. The left ventricles
were homogenized in a modified RIPA buffer (50 mM
Tris, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 % NP-40,
0.25 % Na-deoxycholate) supplemented with protease in-
hibitor cocktail (Roche). On whole lysate, we evaluated
caspase 9 protein levels (total and cleaved products), the
ratio of phosphorylated and total MLC2, and ratio of
phosphorylated and total ERK1/2. For analysis of mito-
chondrial and cytosolic proteins involved in apoptosis
activation signaling pathway, subcellular protein frac-
tions have been extracted using the ProteoExtract Sub-
cellular Proteome Extraction kit (Calbiochem) following
the manufacturer’s protocol.
For immunoblotting, 10 μg of protein was separated
by 12 or 15 % SDS-polyacrylamide gel electrophoresis
(PAGE) and subsequently transferred to a polyvinylidene
difluoride (PVDF) membrane. Adequate transfer of pro-
tein was confirmed by Ponceau Red staining of the mem-
branes. Antibodies against cytochrome c (Cytochrome C
Releasing Apoptosis Assay Kit (#ab65311, Abcam), Bcl2
(#ab692, Abcam), Acetylcoenzyme A acyltransferase 2
(ACAA2) (#sc-100847, Santa Cruz Biotechnology), TIM23
(#611222 BD Biosciences), MitoProfile® total OXPHOS
Rodent WB Antibody Cocktail (#ab110413, Abcam), my-
osin light chain 2 (MLC2) (#ab92721, Abcam), myosin
light chain (pMLC2) (#ab2480, Abcam), Phospho-p44/42
MAPK (Erk1/2) (#4370, Cell Signaling), and p44/42
MAPK (Erk1/2) (137F5) (#4695, Cell Signaling) had been
used.
In particular, MitoProfile® total OXPHOS Rodent WB
Antibody Cocktail contains five mAbs, one each against
CI subunit NDUFB8 (ab110242), CII-30 kDa (ab14714),
CIII-Core protein 2 (ab14745) CIV subunit I (ab14705),
and CV alpha subunit (ab14748) as an optimized pre-
mixed cocktail. The kit is suitable for western blotting
analysis of the relative levels of the five OXPHOS com-
plexes in mitochondrial preparations from mouse.
Equal protein loading and fractions purity were con-
firmed by probing for α-tubulin for whole lysate or
cytosolic fraction and mitochondrial OXPHOS complex
II protein for mitochondrial fraction.
Immunoreactive proteins were detected using ECL
Plus (GE Healthcare) and quantified by the ImageJ
1.41 version software. At least, all samples were eval-
uated as duplicates. Representative western blots of
all measured proteins are shown in Additional file 1:
Figures S2-S4.
Statistics
Data are shown as mean ± standard error of the mean
(SEM). We only included animals with cannulation
times less than 2 min and coronary flow between 1 and
4 ml/min at the end of the stabilization phase. Parame-
ters were tested by one-way ANOVA followed by post
hoc Dunnett comparing all treated groups with the un-
treated. For RPP, additionally we performed two-sided T
test for independent samples. p values ≤0.05 were con-
sidered statistically significant.
Results
Pre-treatment with ERβ agonist and E2 improved LV
function after I/R
Developed left ventricular pressure (LVPdp) and rate
pressure product (RPP) showed a significant better re-
covery in ERβA- and E2-treated groups compared with
controls (Fig. 1a, b). Markers for contractility and relax-
ation, i.e., dP/dtmax and dP/dtmin, were significantly im-
proved in the groups treated with ERβA or E2 (Fig. 1c, d).
Heart rate (HR) was not changed significantly after I/R in
all groups. All raw data are shown in the Additional file 1:
Figure S1.
Effect of ERβ agonist and E2 on necrosis and apoptosis
after I/R
LDH in the effluent of isolated hearts, a marker of ne-
crosis, was measured immediately before ischemia and
3, 6, 9, and 12 min immediately after start of reperfu-
sion. All groups showed a peak in LDH levels between 3
and 6 min post-ischemia, which were significantly de-
creased only in the E2 group (Fig. 2). Pre-treatment with
ERβA showed a similar effect that did not reach statis-
tical significance.
Assessing apoptosis, we found that the number of
TUNEL-positive cells was significantly decreased by pre-
treatment with ERβA or E2 (Fig. 3a). Cytochrome c release
to the cytosol indicates mitochondrial damage and ac-
tivation of the intrinsic pathway of apoptosis. ERβA,
as well as E2 pre-treatment, significantly decreased
cytochrome c levels in cytosolic fractions after I/R
(Fig. 3b). Furthermore, the anti-apoptotic protein Bcl2
was increased in mitochondrial fractions of hearts
pre-treated with ERβA and E2 (Fig. 3c). Expression
levels of the predominant mitochondrial protein
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acetylcoenzyme A acyltransferase 2 (ACAA2) also
known for its anti-apoptotic function [23] were higher
in mitochondrial fractions from hearts treated with
ERβA or E2 after I/R (Fig. 3d). Both ERβA and E2
pre-treatment decreased significantly the levels of cas-
pase 9 and of its cleavage products in whole heart ly-
sates (Fig. 3e, f ).
Mitochondrial integrity is improved by pre-treatment with
ERβA or E2
To assess integrity of the mitochondrial membrane
structure, we also evaluated the effects of ERβA and E2
pre-treatment on the mitochondrial translocase TIM23
that is located in the inner mitochondrial membrane.
We observed significant higher levels of TIM23 protein
Fig. 1 Left ventricular recovery after I/R LV developed pressure (LVPdp) (a). Rate pressure product (RPP) (b). dP/dtmax as marker of LV contractility
(c) and dP/dtmin as marker for LV relaxation (d). Data are shown as mean ± SEM of parameters at the end of I/R in % of the start of ischemia.
Significances were calculated by ANOVA followed by post hoc Dunnet and defined as significant with *p < 0.05
Fig. 2 Measurement of LDH levels in effluents as marker for necrosis. Data shown are mean ± SEM at each time point. Significances were
calculated by ANOVA followed by post hoc Dunnet for each time point and defined as significant with *p < 0.05
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in mitochondrial fractions of ERβA- and E2-treated
groups than in controls (Fig. 4a). Furthermore, the levels
of complex I protein of OXPHOS chain in mitochon-
drial protein fractions in both treated groups (p < 0.05)
were significantly higher than those in untreated con-
trols (Fig. 4b). Together with the reduced cytochrome c
release, these data suggest a better maintenance of mito-
chondrial integrity and respiratory function in the
ERβA- and E2-treated groups.
Myosin light chain 2 phosphorylation by E2 and ERβA
pre-treatment
Phosphorylation status of MLC2 alters Ca2+ sensitivity
of myofilaments and is therefore important for cardio-
myocyte contractility [24, 25]. We measured total MLC2
and phosphorylated levels of MLC2 (pMLC2) as marker
for contractile function in total protein lysates of LV
after I/R. We observed a significant greater degree of
MLC2 phosphorylation in the E2-treated group in com-
parison with controls, which was not found in ERβA-
treated animals (Fig. 5a). ERK1/2 is located upstream of
MLC2 and can phosphorylate MLC2. E2- but not ERβA-
treated mice exhibited a significant higher level of phos-
phorylation of ERK1/2 than controls (Fig. 5b). These
data suggest that E2 but not ERβA improves myocyte
contractility.
Discussion
The present study shows that activation of ERβ, as well
as E2 treatment, prior to I/R attenuates mitochondrial
Fig. 3 Apoptosis evaluation. Calculation of TUNEL-positive cells within the myocardium after treatment with E2 or ERβA (a). Representative pictures of
TUNEL staining and relative protein expression to measure cytochrome c level in cytosolic fraction after treatment with E2 or ERβA (b). Relative protein
expression data for measurement of Bcl2 (c) and ACAA2 (d) in mitochondrial fractions as well as total caspase 9 (e) and cleavage product (f) in whole
cell lysate, Data are shown mean ± SEM. Significances were calculated by ANOVA followed by post hoc Dunnet and defined as significant
with *p < 0.05
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damage and cell death and improves cardiac recovery.
Here we show for the first time that a specific ERβ agon-
ist reduces mitochondria-dependent apoptosis and con-
tributes to the maintenance of mitochondrial integrity
after ischemia and reperfusion injury. Furthermore, we
found an ERβ-independent effect of E2 on MLC2 phos-
phorylation that may contribute to better cardiac con-
tractile recovery under I/R conditions.
Although E2 in various experimental models induces
the improvement of functional cardiac recovery after I/
R, the pathways involved and the relative contribution of
ER subtypes are still a matter of debate. Reduction of in-
farcted necrotic area and improvement of functional in-
dexes recorded in Langendorff experiments already
suggested that E2 can maintain myocardial tissue viability
through reduction of necrosis and apoptosis [7, 15, 26]
and was reproduced in our system. Reduced LDH release
in the first 12 min of reperfusion, indicating early necrosis,
was reduced by E2 treatment, but not by ERβA, indi-
cating that ERα or GPER may also have conferred
cardioprotection. Of note, in our system, a specific ERβ
agonist reduced apoptosis and led to the preservation of
mitochondrial integrity which was associated with a better
cardiac recovery after I/R compared with the untreated.
Apoptosis activation after I/R is driven by the loss of
mitochondrial stability leading to mitochondrial release
and cytosolic activation of cytochrome c [17]. These
events result in mitochondrial dysfunction and cytosolic
caspase activation, which contribute to myocardial con-
tractile dysfunction, necrosis, and apoptosis after reper-
fusion. In particular, we found that both ERβA and E2
increased the amount of the anti-apoptotic protein Bcl2
in the mitochondria.
Contrastly, in a study with prostate cancer tissue from
men, the treatment with the ERβ agonist DPN resulted
in a significant induction of apoptosis [27]. These con-
trary effects of specific ERβ activation can be explained
by the sex-, cell-, and tissue type-specific regulation of
estrogen receptors and its pathways. For example, our
group could show in a study with male and female wild-
type and ERβ-deficient mice that sex differences in the
development of heart failure are related to sex-specific
actions of ERβ. In that study, ERβ promoted fibrosis in
male hearts but inhibited fibrosis in females [28].
Fig. 4 Evaluation of mitochondrial integrity. Relative protein level TIM23 (a) and NDUFB8 of OXPHOS complex I (b) in mitochondrial fractions of
LV protein lysates. Data shown are mean ± SEM. Significances were calculated by ANOVA followed by post hoc Dunnet and defined as significant
with *p < 0.05
Fig. 5 Modulation of contractility. Relative protein phosphorylation of MLC2 (a) and of ERK1/2 (b). Data shown are mean ± SEM. Significances
were calculated by ANOVA followed by post hoc Dunnet and defined as significant with *p < 0.05
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Physiological relevance of our recent finding is sup-
ported by previous studies showing that increased Bcl2
levels are associated with reduced apoptosis, reduced in-
farct size, and improved recovery of cardiac function
after I/R [29, 30]. Moreover, expression of Bcl2 is con-
trolled by ERβ. Bcl2 family proteins, located in mito-
chondrial membranes, provide protection against pro-
apoptotic stimuli [17]. Bcl2 prevents permeabilization of
the outer mitochondrial membrane [31] and thereby
prevents the release of cytochrome c from mitochondria.
Accordingly, we found lower cytochrome c levels in the
cytosol of ERβA- and E2-treated hearts than in controls
after I/R. The downstream apoptotic pathway induced
by cytochrome c release from the mitochondria is the
cytosolic recruitment and activation of caspase cascade in
the apoptosome [17]. Accordingly, we found a significant
downregulation in total and cleaved caspase 9 in E2- and
ERβA-treated groups suggesting that E2 via ERβ can
modulate caspase 9 through two mechanisms: a direct in-
hibition of pro-caspase 9 synthesis and an indirect effect
through a decrease in caspase 9 activation by cytochrome
c. Since caspase inhibitors reduce infarct size [32, 33], ERβ
modulation of caspases could be cardioprotective.
In ERβA- and E2-treated groups, we also found higher
protein levels of ACAA2. ACAA2 is a mitochondrial en-
zyme involved in lipid metabolism that was identified as
a binding partner for the pro-apoptotic protein Bcl2 and
19-kDa interacting protein-3 (BNIP3) [23, 34]. ACCA2
can abolish BNIP3-mediated apoptosis and mitochon-
drial damage in hepatic and osteoclastic cell lines [23]. It
is likely that similar mechanisms might occur in cardio-
myocytes in response to I/R. We therefore conclude that
ERβ reduces mitochondria-related apoptosis through
several mechanisms.
Mitochondria in the ERβA and E2 pre-treated groups
had higher levels of TIM23, a marker of integrity of the
mitochondrial inner membrane [35]. This is the first time
that an interaction between TIM23 and E2/ERβ signaling
in cardiac damage due to I/R is reported. This increase in
TIM23 protein levels together with the reduced cyto-
chrome c release and the higher expression of anti-
apoptotic proteins suggests that E2 induced stabilization
of mitochondrial structure and integrity by activating ERβ.
The respiratory chain in the inner mitochondrial
membrane is responsible for generating ATP and con-
sists of five major membrane protein complexes. We
found here that the pre-treatment with ERβA and E2 in-
creases the protein levels of mitochondrial complex I,
supporting the notion that E2 reduces I/R damage
through an ERβ-dependent mechanism.
Other mechanisms could contribute to the better con-
tractile recovery after I/R in ERβA and E2 pre-treated
hearts. Our group previously reported that E2 treatment
can modulate myocardial contractility via MLC2 function
in a sex-specific manner [21]. We observed an increase in
phosphorylation of MLC2 in E2- but not in ERβA-treated
groups. Since ERK1/2 acts upstream of MLC2 leading to its
phosphorylation [36], we assessed ERK1/2 phosphorylation
and found that it was increased only in the E2-treated
group. These findings suggest that E2 leads to MLC2 phos-
phorylation by an ERβ-independent mechanism.
This study has several limitations. Most importantly,
we did not confirm the specificity of the ERβA. This has
however been well established in previous investigations
[8]. We limited our study to a single dose of ERβA and
E2, which does not exclude varying effects at different
doses. We also used females only. Since we have previ-
ously shown sex-specific effects of E2 in cardiac cells
and tissues [21, 22, 28, 37], it will be interesting to assess
the effects of ERβ activation under I/R also in males.
Conclusions
The present study suggests that the activation of ERβ by
E2 or a specific agonist essentially contributes to a re-
duction of cardiac stress by reducing apoptosis and pres-
ervation of mitochondrial integrity, and improved
functional recovery after I/R. The identification of new
ERβ-mediated E2 effects opens new opportunities to
therapeutically targeting these pathways in different clin-
ical settings.
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Additional file 1: Figure S1. Raw data of cardiac function during
ischemia and reperfusion. Data are shown as mean ± SEM. Significances
were calculated by ANOVA followed by post hoc Dunnet and defined as
significant with p < 0.05. Figure S2: Representative western blots of
ACAA2, Bcl2, TIM23, NDUFB8 and cytochrome c in cytosolic (F1) and
mitochondrial (F2) fractions and corresponding controls (tubulin for F1,
complex II for F2). Figure S3: Representative western blots of whole tissue
lysates for caspase 9, caspase 9 cleaved and corresponding loading
controls (tubulin and GAPDH). Figure S4: Representative western blots of
whole tissue lysates for MLC/pMLC and ERK/pERK. (DOCX 876 kb)
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